These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6210682)

  • 1. Antibiotic combinations against gram-negative bacilli and Staphylococcus aureus in cancer patients: comparative in-vitro and in-vivo activity of cefoperazone and mezlocillin singly or combined together.
    Standiford HC; Viollier AF; Moody M; Klastersky J; Tatem B; Schimpff SC
    J Antimicrob Chemother; 1982 Jan; 9 Suppl A():47-9. PubMed ID: 6210682
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus.
    Lagast H; Klastersky J; Standiford H; Viollier A
    Infection; 1984; 12(3):190-3. PubMed ID: 6432702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in-vitro activity of mezlocillin against community hospital isolates in comparison to other penicillins and cephalosporins.
    Parry MF; Folta D
    J Antimicrob Chemother; 1983 May; 11 Suppl C():97-102. PubMed ID: 6619043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic action between sisomicin and mezlocillin against gram-negative bacteria and Staphylococcus aureus.
    Soares LA; Trabulsi LR
    Arzneimittelforschung; 1979; 29(12a):1934-7. PubMed ID: 543894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of mezlocillin and azlocillin with cephalosporin antibiotics: cefoxitin, cefoperazone, cefotaxime and moxalactam.
    Neu HC; Labthavikul P
    J Antimicrob Chemother; 1982 Jan; 9 Suppl A():101-6. PubMed ID: 6281229
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antibiotic therapy for severe gram-negative infections].
    Vildé JL; Leport C
    Rev Prat; 1983 Jan; 33(3):117-24. PubMed ID: 6844820
    [No Abstract]   [Full Text] [Related]  

  • 7. Flavobacterium meningosepticum ventriculitis: in vivo and in vitro results with the combinations rifampicin-erythromycin and mezlocillin-cefoxitin.
    Kelsey MC; Emmerson AM; Drabu Y
    Eur J Clin Microbiol; 1982 Jun; 1(3):138-43. PubMed ID: 6217065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo microbiological evaluations of cefoperazone.
    Renzini G; Ravagnan G; Piccolomini R; Dainelli B; Comanducci A
    Clin Ther; 1980; 3(Spec Issue):139-44. PubMed ID: 6446388
    [No Abstract]   [Full Text] [Related]  

  • 9. Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patients.
    Jones P; Bodey GP; Rolston K; Fainstein V; Riccardi S
    Am J Med; 1988 Jul; 85(1A):3-8. PubMed ID: 3400680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus.
    Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y
    J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center.
    Rolston KV; Elting L; Waguespack S; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1996; 42(5):348-53. PubMed ID: 8874974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new cephalosporins and penicillins.
    Weinstein AJ
    Compr Ther; 1982 Feb; 8(2):26-31. PubMed ID: 6279354
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antibacterial activity of the combination of cefoperazone piperacillin].
    Krüger E; Machka K; Braveny I
    Arzneimittelforschung; 1983; 33(4):571-4. PubMed ID: 6223645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mezlocillin for treatment of infections in cancer patients.
    Issell BF; Bodey GP
    Antimicrob Agents Chemother; 1980 Jun; 17(6):1008-13. PubMed ID: 6447474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.
    Brogden RN; Carmine A; Heel RC; Morley PA; Speight TM; Avery GS
    Drugs; 1981 Dec; 22(6):423-60. PubMed ID: 6459224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimum inhibitory concentrations for selected antimicrobial agents against organisms isolated from the mammary glands of dairy heifers in New Zealand and Denmark.
    Salmon SA; Watts JL; Aarestrup FM; Pankey JW; Yancey RJ
    J Dairy Sci; 1998 Feb; 81(2):570-8. PubMed ID: 9532511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.
    Seibert G; Isert D; Klesel N; Limbert M; Markus A; Schrinner E
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():25-30. PubMed ID: 1601753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of ticarcillin and mezlocillin plus sisomicin in Gram-negative bacillary bacteraemia and bronchopneumonia.
    Hanson B; Coppens L; Klastersky J
    J Antimicrob Chemother; 1982 Oct; 10(4):335-41. PubMed ID: 6216236
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the activity of cefoperazone, cefuroxime and cefoxitin against Gram-negative bacilli and synergy studies with cefoperazone and ticarcillin.
    Miles HM; Carson M; Pavillard ER
    Drugs; 1981; 22 Suppl 1():15-9. PubMed ID: 6456885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.